For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.
Population Health Sciences

You are here

Publications

Found 348 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is S  [Clear All Filters]
2019
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2019.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2019.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2019.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2019.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2019.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Meinhofer A, Williams ARobin, Johnson P, Schackman BR, Bao Y.  2019.  Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events? J Subst Abuse Treat. 105:37-43.
Kennel PJ, Kneifati-Hayek J, Bryan J, Banerjee S, Sobol I, Lachs MS, Safford MM, Goyal P.  2019.  Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES).. BMC Cardiovasc Disord. 19(1):76.
Kennel PJ, Kneifati-Hayek J, Bryan J, Banerjee S, Sobol I, Lachs MS, Safford MM, Goyal P.  2019.  Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES).. BMC Cardiovasc Disord. 19(1):76.
Sterling MR, Jannat-Khah D, Bryan J, Banerjee S, McClure LA, Wadley VG, Unverzagt FW, Levitan EB, Goyal P, Peterson JC et al..  2019.  The Prevalence of Cognitive Impairment Among Adults With Incident Heart Failure: The "Reasons for Geographic and Racial Differences in Stroke" (REGARDS) Study.. J Card Fail. 25(2):130-136.
Sterling MR, Jannat-Khah D, Bryan J, Banerjee S, McClure LA, Wadley VG, Unverzagt FW, Levitan EB, Goyal P, Peterson JC et al..  2019.  The Prevalence of Cognitive Impairment Among Adults With Incident Heart Failure: The "Reasons for Geographic and Racial Differences in Stroke" (REGARDS) Study.. J Card Fail. 25(2):130-136.
Casalino LP, Saiani R, Bhidya S, Khullar D, O'Donnell E.  2019.  Private Equity Acquisition of Physician Practices.. Ann Intern Med. 171(1):78.
Hood JE, Behrends CN, Irwin A, Schackman BR, Chan D, Hartfield K, Hess J, Banta-Green C, Whiteside L, Finegood B et al..  2019.  The projected costs and benefits of a supervised injection facility in Seattle, WA, USA.. Int J Drug Policy. 67:9-18.
Subbaramaiah K, Iyengar NM, Morrow M, Elemento O, Zhou XKathy, Dannenberg AJ.  2019.  Prostaglandin E down-regulates sirtuin 1 (SIRT1), leading to elevated levels of aromatase, providing insights into the obesity-breast cancer connection.. J Biol Chem. 294(1):361-371.
Yin MT, RoyChoudhury A, Bucovsky M, Colon I, Ferris DC, Olender S, Agarwal S, Sharma A, Zeana C, Zingman B et al..  2019.  A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV.. J Acquir Immune Defic Syndr. 80(3):342-349.
Yin MT, RoyChoudhury A, Bucovsky M, Colon I, Ferris DC, Olender S, Agarwal S, Sharma A, Zeana C, Zingman B et al..  2019.  A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV.. J Acquir Immune Defic Syndr. 80(3):342-349.
Bond AM, Volpp KG, Emanuel EJ, Caldarella K, Hodlofski A, Sacks L, Patel P, Sokol K, Vittore S, Calgano D et al..  2019.  Real-time Feedback in Pay-for-Performance: Does More Information Lead to Improvement? J Gen Intern Med.
Bond AM, Volpp KG, Emanuel EJ, Caldarella K, Hodlofski A, Sacks L, Patel P, Sokol K, Vittore S, Calgano D et al..  2019.  Real-time Feedback in Pay-for-Performance: Does More Information Lead to Improvement? J Gen Intern Med.
Shi Y, Liang D, Bao Y, An R, Wallace MS, Grant I.  2019.  Recreational marijuana legalization and prescription opioids received by Medicaid enrollees.. Drug Alcohol Depend. 194:13-19.
Tran B, Sedrakyan A, Flynn P, Altorki N, Jorm L, Wright G.  2019.  Reintervention and Survival After Limited Lung Resection for Lung Cancer Treatment in Australia.. Ann Thorac Surg. 107(5):1507-1514.
Behrendt C-A, Kölbel T, Debus ESebastian, Rieß HChristian, Sedrakyan A.  2019.  Reply.. J Vasc Surg. 69(4):1328.
Da Cunha RJ, MacMahon A, Jones MT, Savenkov A, Deland J, Roberts M, Levine D, Elliot A, Kennedy J, Drakos M et al..  2019.  Return to Sports and Physical Activities After First Metatarsophalangeal Joint Arthrodesis in Young Patients.. Foot Ankle Int. 40(7):745-752.
Venkatesan T, Levinthal DJ, Li BUK, Tarbell SE, Adams KA, Issenman RM, Sarosiek I, Jaradeh SS, Sharaf RN, Sultan S et al..  2019.  Role of chronic cannabis use: Cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome.. Neurogastroenterol Motil. 31 Suppl 2:e13606.
Venkatesan T, Levinthal DJ, Li BUK, Tarbell SE, Adams KA, Issenman RM, Sarosiek I, Jaradeh SS, Sharaf RN, Sultan S et al..  2019.  Role of chronic cannabis use: Cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome.. Neurogastroenterol Motil. 31 Suppl 2:e13606.
Venkatesan T, Levinthal DJ, Li BUK, Tarbell SE, Adams KA, Issenman RM, Sarosiek I, Jaradeh SS, Sharaf RN, Sultan S et al..  2019.  Role of chronic cannabis use: Cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome.. Neurogastroenterol Motil. 31 Suppl 2:e13606.
Venkatesan T, Levinthal DJ, Li BUK, Tarbell SE, Adams KA, Issenman RM, Sarosiek I, Jaradeh SS, Sharaf RN, Sultan S et al..  2019.  Role of chronic cannabis use: Cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome.. Neurogastroenterol Motil. 31 Suppl 2:e13606.